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Worldwide, breast cancer incidence has been increasing for decades. Exposure to reproductive
hormones, as occurs with recurrent menstrual cycles, affects breast cancer risk, and can promote
disease progression. Exogenous hormones and endocrine disruptors have also been implicated in
increasing breast cancer incidence. Numerous in vitro studies with hormone-receptor-positive cell
lines have provided insights into the complexities of hormone receptor signaling at the molecular
level; in vivo additional layers of complexity add on to this. The combined use of mouse genetics
and tissue recombination techniques has made it possible to disentangle hormone action in vivo
and revealed that estrogens, progesterone, and prolactin orchestrate distinct developmental
stages of mammary gland development. The 2 ovarian steroids that fluctuate during menstrual
cycles act on a subset of mammary epithelial cells, the hormone-receptor-positive sensor cells,
which translate and amplify the incoming systemic signals into local, paracrine stimuli. Progester-
one has emerged as a major regulator of cell proliferation and stem cell activation in the adult
mammary gland. Two progesterone receptor targets, receptor activator of NfB ligand andWnt4,
serve as downstreamparacrinemediators of progesterone receptor-induced cell proliferation and
stem cell activation, respectively. Some of the findings in themouse have been validated in human
ex vivomodels andbynext-generationwhole-transcriptome sequencingonhealthy donors staged
for their menstrual cycles. The implications of these insights into the basic control mechanisms of
mammary gland development for breast carcinogenesis and the possible role of endocrine dis-
ruptors, in particular bisphenol A in this context, will be discussed below. (Endocrinology 156:
3442–3450, 2015)
Breast cancer affects 1 in 8women inWestern countries(1). The disease is heterogeneous: more than 20 dis-
tinct histopathological subtypes are recognized (2). Of
clinical relevance are tumor grade and tumor stage, aswell
as classification according to estrogen receptor (ER) and
progesterone receptor (PR) status, as assessed by immu-
nohistochemistry (IHC), andHER2overexpressiondue to
amplification, as determined by IHC and fluorescent in
situ hybridization. Five major molecular breast cancer
subtypes were discerned by global gene expression profil-
ing and largely correspond to IHC subtype, with luminal
A representing ER, of low grade and low Ki67 index;
Luminal B, ER of higher grade and proliferative index;
HER2beingHER2by IHCand eitherERorER; and
the “basal-like,”which are dubbed triple negative because
they do not express any of the 3 receptors. The last is a
heterogeneous group that contains further subtypes (3).
More than 2 thirds of all breast cancers are luminal, ie,
ER, and differ in biology and clinical course from
HER2 and basal-like tumors (4).
Tamoxifen is a selective ER modulator, which was in-
troducedover 40 years ago andhas dramatically increased
survival of ER breast cancer patients (5). ER signaling
can now also be inhibited by pure ER antagonists, such as
fulvestrant, or indirectly by aromatase inhibitors, which
are the mainstay in the therapy of most postmenopausal
breast cancer patients. Although most ER tumors ex-
press ER in at least 90% of the cells, some cancers have
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lower percentages of ER tumor cells, but are still clas-
sified as ER as long as at least 1% of the tumor cells
express ER (6). The ER signaling pathway has long been
a major focus of research in the breast cancer field; al-
though it is of premier importance in the therapy of ER
breast cancer, other hormonal factors are increasingly
considered toplay an important role in thepathogenesis of
the disease (7–9). Here, we will discuss how endogenous
hormones, in particular progesterone, impinge on the
breast and their role in tumor development, and we will
attempt to integrate exposure to endocrine disruptors into
this picture, taking the widely distributed bisphenol A
(BPA) as an example.New insights in this area are relevant
to breast cancer prevention but may also be explored for
novel therapeutic approaches.
Hormonal risk factors
Ovariectomy (10) was shown to benefit individual breast
cancer patients more than 100 years ago. Epidemiological
studies revealed that breast cancer risk increases with the
number of menstrual cycles a woman experiences in her
lifetime (11): early menarche, late menopause, and short
menstrual cycles all increase risk (12). Based on breast
cancer statistics from the seventies that were not con-
founded by hormone replacement therapy (HRT), Pike et
al (11) calculated that if it were not for menopause there
would be 6 times as many cases of breast cancer (11, 13).
More recently, it was shown that the risk related to men-
strual cycles applies to all subtypes of breast cancer (14).
Young age at first pregnancy has a protective effect (15,
16); more detailed data from the Nurses Health Study
indicates that this applies to hormone-receptor-positive,
more specifically PR, breast cancers (14). The protective
effects of early pregnancy rely on a number of factors:
lower levels of GH (17) and prolactin (18) after a first
pregnancy, changes in stem cell numbers and biology,
changes in p53 functional status (19), and differences in
the proliferative response have all been implicated (20).
Large women’s health studies revealed that breast can-
cer risk related toHRT increases when an estrogenic com-
pound is combined with progestin (21–23), whereas es-
trogens on their own can have protective effects (24).
Indeed, since HRT was discontinued, breast cancer inci-
dence has diminished (25). Similarly, womenwho are cur-
rently on oral contraception, most of which consists of
ethinyl estradiol and a progestin, have a 24% increased
risk of getting breast cancer, which decreases once they
stop taking the pill (26).
Role of Hormones in the Breast
The breast is a unique organ in that it develops primarily
after birth, under the control of hormones (Figure 1) (27).
A rudimentary ductal system present at birth begins to
unfold during puberty and gains in complexity during
adulthood with recurrent hormone stimulation during
menstrual/estrous cycles. During pregnancy, ductal
complexity increases further and finally secretory struc-
tures of saccular shape, called alveoli, bud all over the
ductal system. Its embryonic-like state after birthmakes
the breast exquisitely plastic and particularly suscepti-
ble to carcinogenesis.
The mouse mammary gland has served as a model to
study gene function in vivo and to genetically dissect gene
function indevelopment.A largenumberofmousemutant
strains are available, and tissue recombination experi-
ments allow one to generate epithelial specific mutants
(27). This approach has revealed thatmammary epithelial
intrinsic ER signaling is required for pubertal ductal
elongation (28). PR is essential in the mammary epithe-
lium for side branching and alveologenesis (29), whereas
the epithelial prolactin receptor is required for alveolo-
genesis and milk secretion (Figure 1) (30).
Figure 1. Mammary gland development in the mouse. Schematic representation of distinct stages of postnatal mammary gland development. In
the pubertal mammary gland, terminal end buds appear at the tips of the ducts triggered by ovarian estrogens, which require epithelial ER. The
ducts elongate and bifurcate until the edges of the fat pad are reached, which coincides with sexual maturity. Repeated stimulation with
progesterone, as occurs during estrous cycles, results in the formation of side branches, which bud from preexisting ducts at a 90° angle. Side
branch formation is blocked in PR/ mammary epithelia. Ductal complexity continues to increase during the first half of pregnancy. In the last
third of pregnancy, secretory structures of saccular shape, alveoli, sprout all over the ductal system and differentiate into milk-producing units
under the control of prolactin receptor signaling.
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On the one hand, different hormone receptor signaling
pathways are limiting at distinct developmental stages.On
the other hand, the mammary epithelium responds differ-
ently to a hormonal stimulus depending on its develop-
mental stage. Hormone ablation and replacement exper-
iments have shown that 17--estradiol induces cell
proliferation specifically in pubertal (31) but not in adult
mammary glands. In the adult, ie, more than 8-week-old,
femalemouse, 17--estradiol pretreatment induces the ex-
pression of PR (32), whereas subsequent stimulation with
progesterone triggers proliferation (33). Hence, in the
adult female PR signaling is the major stimulus of cell
proliferation.
Human Breast
The anatomy of the human breast with its 15–25 ducts
that each give rise to a lobe containing multiple terminal
ductal lobular units and 2 distinct stromal compartments,
the intralobular and interlobular stroma, ismore complex
than that of themousemammary gland,which has a single
stem ductal tree embedded in a homogeneous fatty
stroma. Nevertheless, in terms of hormonal regulation,
there seem to be substantial similarities across species. In
most mammals, the ovaries first secrete estrogens in re-
sponse to increased secretion of gonadotropins, and sex-
ual maturity coincides with the establishment of cyclic
peaks of ovarianprogesterone secretion. Progesterone lev-
els increase after ovulation when the body anticipates
pregnancy, and continue to rise when pregnancy is
established.
Pathologists observe proliferative activity in the breast
epitheliumduring the luteal phase,whenprogesterone lev-
els peak (Figure 2) (34, 35), suggesting that mouse and
human mammary epithelia may indeed be similarly reg-
ulated, at least with regards to hormonal control of cell
proliferation. Recently developed ex vivo models of the
human breast have shown that progesterone elicits cell
proliferation (36, 37). Of note, the dog, a species with
particularly long luteal phase, is especially prone to mam-
mary carcinoma (38)
Cellular and Molecular Mechanisms of
Progesterone Action in the Mammary
Epithelium
Cell proliferation
The mammary epithelium is bilayered: the inner layer
of luminal cells is surrounded by ameshwork of elongated
myoepithelial cells, which are in close contact with the
basal membrane. Luminal cells touch the lumen and are
frequently opposed to the cells that are summarized under
the term“basal cells”: the subluminal,myoepithelial, pro-
genitor, and stem cells. Between 30% and 50% of the
luminal cells express ER in the adult female, whether ro-
dent or human (39, 40). Because PR is an ER target gene,
it is coexpressed in the same cells, although evidence has
emerged that, at least in the human breast, PR is also in-
dependently expressed (41, 42). In the adult mammary
epithelium, most cell proliferation occurs in the luminal
compartment, but fewof the proliferating cells express ER
and PR (39). When mammary epithelial cells that are PR
deficient (genetically PR/) are grafted on their own to
clearedmammary fat pads, they hardly proliferate in adult
hosts. However, when the PR/ mammary epithelial
cells are intermingledwithPRwtmammary epithelial cells
in a 1 to 10 ratio, they proliferate and contribute to all
aspects of mammary gland development in the context of
the resulting chimeric epithelia (29), indicating that PR
signaling can occur in a paracrine fashion. The same ap-
plies to ER/ mammary epithelial cells, which, when
grafted on their own, fail to proliferate at all, but which
contribute to all aspects of mammary gland development
in the context of chimeric epithelia (28). Thismotivates us
toname the cells expressingERandPR“sensor cells” (43),
because they relay the systemic signal to local partners by
emitting paracrine signals (Figure 3).
Figure 2. The human menstrual cycle. Graph showing serum levels of
the major fluctuating hormones across a menstrual cycle. Note that
progesterone levels peak during luteal phase. Estrogen reaches its
maximum levels during follicular phase; a smaller peak follows during
luteal phase. Cell proliferation is observed in the breast epithelium in
the luteal phase and positively correlated with serum progesterone
levels.
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When adult female mice are hormonally ablated and
subsequently pretreated with estrogens, progesterone in-
duces cell proliferation in 2 waves. During the first 24
hours, PR cells proliferate, whereas proliferation of
PR cells is observed subsequently (44). The first, small
wave of cell-intrinsic proliferation requires cyclin D1;
whether this relates to its cell cycle and/or its transcription-
related functions is unclear. Support for such scenarios can
be found in observations from the PR breast cancer cell
line T47D, which reveal both that PR and CyclinD1 in-
teract physically and are found in transcription complexes
that bind toDNAand that down-modulation ofCyclinD1
expression blocks PR-B-induced gene transcription (45).
The second wave of cell proliferation, induced by a para-
crine mechanism, is larger and relies on a tumor necrosis
family member, receptor activator of NfB ligand
(RANKL). Progesterone increases RANKL mRNA ex-
pression by a posttranscriptional mechanism stabilizing
themRNA (36). RANKLprotein is detected exclusively in
PR cells (44, 46). Whether RANKL itself acts as mito-
gen, or removes a growth-inhibitory signal, or acts
through a more complex loop involving other cell types,
possibly infiltrating immune cells known to express the
receptor, awaits further clarification. Although individual
cells in luminal and abluminal locations express the cog-
nate receptor RANK (47), it remains to carry out costain-
ings to determine whether RANK cells are actively cy-
cling epithelial cells.
Stem cell activation
During luteal phase, stem cells are likely to be activated
in anticipation of the cell number expansion of pregnancy.
Stem cells have been studied by 2 major approaches, one
entailing fluorescence-activated cell
sorting, to enrich for cells with the
ability to reconstitute mammary
glands divested of their endogenous
epithelium, and the other lineage
tracing. Stem cells as defined by the
first approach are located in the
basal layer and express high levels of
integrin 1 and 6 (48, 49) and have
been shown to expand in response to
hormone stimulation (50, 51). Lin-
eage-tracing experiments indicated,
however, that most postnatal cell
proliferation derives from luminally
restricted stem cells (52, 53). To as-
sess the role of PR signaling in stem
cell function comprehensively, we
resorted to serial transplantation.
Mammary epithelium can reconsti-
tute up to 7 transplant cycles (54).
When we compared PR/ and PRwt epithelia by serially
transplanting them in contralateral glands, PRwt only
slightly decreased in fat pad reconstitution over 4 gener-
ations, but PR/ failed to reconstitute at the third gen-
eration, indicating that PR signaling is required to expand
the stem cell pool during puberty and in adult life (55).
Wnt signaling is important to adult stem cells in many
tissues, including the mammary gland (56), leading us to
wonderwhetherwnt4,whichwehadpreviously identified
as an important paracrine mediator of progesterone func-
tion in the mammary epithelium (57), affects stem cell
function. Serial transplantation revealed that deletion of
wnt4 reduced regenerationpotentialmore thandeletionof
PR did, indicating that wnt4 is of central importance for
regeneration potential and thatwnt4 has PR-independent
functions. Indeed,wnt4 is transcribed as early as postnatal
day 5 in themouse, ie, before detectable progesterone syn-
thesis and PR expression in the mammary epithelium.
Perinatalwnt4 expression is independent of epithelial ER
and PR signaling and is biologically relevant, as shown
with a conditional allele in young animals, where it results
in slightly delayed ductal outgrowth.
In the mammary epithelium of adult females, wnt4 is
exclusively transcribed in PR cells (55). Thus,wnt4, like
RANKL, is a paracrine factor that is synthesized in PR
cells and, as observed for RANKL, not all PR cells ex-
press wnt4.
Wnt4 can activate both canonical and noncanonical
Wnt signaling (58, 59). An Axin2::LacZ reporter that re-
flects canonical Wnt signaling activity in multiple target
tissues (60) revealed activity in the basal cells that corre-
lates with wnt4 expression, peaking in diestrous and in
Figure 3. Signaling downstream of progesterone. Schematic representation of the bilayered
mammary epithelium and the intra- and intercellular signaling activated by progesterone. An
inner, luminal layer is surrounded by myoepithelial/basal cells, which are in contact with the basal
lamina. Progesterone binds its receptor in a subset of HR luminal cells, the sensor cells (light
blue). In certain PR cells, it induces cell proliferation by a Cyclin D1-dependent mechanism (cell-
intrinsic signaling). It induces RANKL, which elicits cell proliferation in neighboring HR cells
(paracrine homotypic) and wnt4, which acts on myoepithelial cells (paracrine heterotypic) and
increases stem cell activity.
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early pregnancy. Deletion of either wnt4 or PR in the
mammary epithelium abrogates this activity, indicating
that canonicalWnt signaling in the basal cells requires PR
and wnt4.
Wnt4 emerges as central activator of mammary epithe-
lial stemcells andof their niche(s).On the onehand, itmay
act directly on bipotent or basally restricted stem cells
located in the basal layer,which can be identified based on
expression of the protein c receptor, itself a Wnt target
gene (61). In this, Wnt4 is helped by a membrane protein
expressed in hormone receptor negative cells, R-spondin
1, which enhances canonical Wnt signaling and is itself
induced by hormone stimulation (62). On the other hand,
wnt4may act directly, possibly via noncanonicalWnt sig-
naling and/or indirectly via distinct paracrine signals on
luminally restricted stem cells. A potential paracrine me-
diator is GH, which can be synthesized in the breast epi-
thelium and has been implicated in progesterone-induced
activation of stem cells in the human breast, in work in-
spired by observations on dogs (63).
Two lines of work suggest that at least some of the
findings in rodent models are of relevance to humans.
First, work with a novel ex vivo model for the human
breast consisting of tissue microstructures isolated from
fresh reduction mammoplasty specimens that remain re-
sponsive to hormones, has shown that progesterone trig-
gers cell proliferation in the adult human breast tissue and
that it induces the expression ofRANKL andWNT4 tran-
scripts (36, 37). Second, next-generation whole transcrip-
tome sequencing was used to analyze global gene expres-
sion in the breast epithelium from 20 premenopausal
women, who were not affected by breast cancer and do-
nated breast tissue to the Susan G. Komen for the Cure
Tissue Bank (http://komentissuebank.iu.edu/), and who
were carefully staged for the menstrual cycle (64). This
study revealed 255 genes that are differentially expressed
between follicular and luteal phase, with 221 increased in
luteal phase; in functional terms these genes related to cell
cycle and mitosis, and DNA damage and repair, as also
observed in vitro (65, 66). Interestingly, this unbiased ap-
proach identified 3 paracrine factors: RANKL, WNT4,
and epiregulin (64).
Additional Complexities
These findings suggest that PR signaling and its down-
stream effectors activate biological processes, such as cell
proliferation and stem cell activation, that may account
for the tumor-promoting effects of recurrent menstrual
cycles. The same mechanisms may be activated when ex-
ogenous progestins are administered, as in the context of
HRTandoral contraception.However, PR signaling itself
is context-dependent, and not all PR signaling is tumor
promoting. Pregnancies have a protective effect early in
life with a 50% reduction in lifetime risk of breast cancer
before the ageof20 (15).However, theybringonveryhigh
levels of progesterone, with serum progesterone reaching
180 ng mL1 in the third trimester, compared with 8–33
ngmL1 in luteal phase and 0.1–0.8 ngmL1 in follicular
phase. Thus, the biological effects of progesterone may
depend on the dose, the duration of the stimulus, the pres-
ence of concomitant high levels of 17--estradiol and
other hormones, as well as on the woman’s age.
A third ovarian hormone, testosterone, fluctuates to
someextentduring themenstrual cyclewithamodestpeak
3 days before the LH peak (67, 68). Interestingly, testos-
terone was reported to be the only hormone, the blood
levels of which correlated with breast cancer risk in
womenwith regularmenstrual cycles (69).Whether cyclic
activities of this hormone contribute to the risk associated
withmenstrual cycles needs tobe explored.The role of this
hormone in tumorigenesis is complex and dependent on
the ER status of the tumor, as reviewed in Ref. 70.
A number of other hormones impinge on the basic reg-
ulatory network controlled by the ovarian hormones (71).
They may serve to fine-tune the system or have distinct
functions. In this context, an extensive study of normal
human breast samples is of interest. It revealed 7 subsets
ofHR cells, all ofwhich are luminal in the humanbreast:
ER, androgen receptor (AR), vitamin D receptor
(VDR), ERAR, ERVDR, ARVDR, and
ERARVDR. Other hormone receptors that were
tested, including thyroid hormone receptor-, thyroid
hormone receptor-, parathyroid hormone 1 receptor,
oxytocin receptor, various somatostatin receptors,RAR,
RAR, RXR, and RXR, did not show a bimodal ex-
pression pattern (72). It will be of interest to see whether
these populations of HR cells are conserved across spe-
cies and whether the distinct receptor expression patterns
characterize distinct cell types with specific biological
function.
Tumor-Promoting Action of Progesterone
Basedon theabove,weproposeamodelofmenstrual cycle
effects on breast carcinogenesis (Figure 4), in which the
repeated activation of PR signaling during luteal phase
may be tumor promoting. Some of the effects of proges-
terone are cell-intrinsic, but many biological responses
rely on paracrine signaling that can be homotypic, ie, to
neighboring luminal cells, or heterotypic, ie, to the
myoepithelium and possibly to stromal cell types.
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Tumor-promoting effects of progesterone are also ob-
served in rodents, where chemically (7,12-Dimethylbenz-
anthracene)-induced carcinogenesis is enhanced/acceler-
atedbyprogesterone/progestin administration (73, 74). In
support of this model, pharmacologically or genetically
blocking RANKL delayed tumorigenesis (47, 75). Inter-
estingly, RANKL inhibition was not effective anymore
once the tumor was fully established (47), suggesting that
the PR/RANKL axis is important specifically early in the
pathogenesis of mammary carcinomas.
Similarly, theWnt signaling path-
way may promote tumorigenesis. In
themouse,wnt1, awnt4 cousin, was
long identified as an oncogene by
cloning of the frequent insertion site
of the oncogenic mouse mammary
tumor virus (76). Ectopic expression
ofWnt1 in themammary epithelium
results in highly penetrant wide-
spread hyperplasia and, ultimately,
tumors (77), consistent with an early
tumor-promoting effect that may
rely largely on indirect and niche-re-
lated effects. In T47D cells, Wnt1 is
a PR-B target and induces matrix
metalloproteases to shed epidermal
growth factor receptor ligands that
transactivate the epidermal growth
factor receptor (78).
Endocrine Disruption
The highly complex network of hor-
mones that orchestrates the develop-
ment of themammary gland through
different phases of its life cycle is still
incompletely understood. There are
concerns that endocrine-disrupting
factors are implicated in breast car-
cinogenesis, because cancer inci-
dence in other hormone-sensitive
organs, such as the prostate and the
testicles are also on the increase.
Determining the role of endocrine-
disrupting compounds in breast
carcinogenesis is an enormous
challenge; these compounds pene-
trate all aspects of our daily lives, so
that exposures are hard to define
and impossible to trace. In addi-
tion, timing of exposure is a major
issue, because hormone action is
highly dependent on developmental stages.
As breast cancer is highly prevalent and multifactorial,
it is impossible to attribute specific cases to exposures,
which are poorly defined. Nevertheless, we would like to
attempt to assess the effect of exposure to BPA, which has
made its way into consumer products and is detected in
body fluids of more than 90% of the population (79).
To assess whether perinatal exposure to BPA affects
mammary gland development, we added concentrations
Figure 4. Model of how endocrine factors affect breast cancer risk. Graph showing breast
cancer risk plotted over a woman’s age, depending on whether or not she was exposed to DES
or BPA. With each menstrual cycle, breast cancer risk increases through progesterone-induced
events during luteal phase. The model proposes that perinatal exposure to endocrine disruptors
increases the sensitivity of the breast to progesterone and hence increases the slope of the curve
(top panel and inset). Various factors such as RANKL, WNT4, epiregulin, CyclinD1, ID4, and
calcitonin, which act through distinct mechanisms and have been shown to have distinct
biologically functions, have been implicated in the biological response to progesterone that may
be amplified due to perinatal exposure.
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ranging from the environmentally relevant 0.6 g/kg per
bodyweight/d to 1.2mg/kg per bw/d to the drinkingwater
of breeding C57Bl6 mice. Hence, the females under ob-
servation were exposed to BPA in utero through their
mothers and during the first 3 weeks of their lives, when
the mother was nursing them, before they were weaned
intoaBPA-free environment.Asdescribed in rats andCD1
mice (80–82),more terminal endbudswere observeddur-
ing puberty; interestingly, at the lowest concentrations of
BPA (83). To assess whether the predominantly proges-
terone-controlled adult mammary epithelium was af-
fected, we assessed cell proliferation. Because subtle in-
creases in cell proliferation indexes are impossible to
discern given the interindividual variation and the impre-
cision of the current available assays, we opted for count-
ing cell numbers in 3-month-old females. The numbers
obtained would reflect accumulated changes due to
slightly increased proliferation rates during each estrous
cycle. After ascertaining by fluorescence-activated cell
sorting analysis that there were no changes in the ratio of
different cell types in mammary glands from exposed and
unexposed females of the same age, cell numbers were
determined. In BPA-exposed animals, cell numbers were
on average 1.5-fold increased. A control group of females,
which had been exposed to diethylstilbestrol (DES), in the
same way showed a 1.7-fold increase in cell number (83).
In order to extrapolate these observations to humans,
let us assume that perinatal exposure is critical during in
utero development (rather than during the nursing period)
and that BPA and DES display analogous behavior with
regard to cell proliferation in mice and breast cancer risk
in women. If women exposed to DES in utero have 1.83
increased relative risk of breast cancer when they are over
40 years old (84), we predict (based on the 1.5- vs 1.7-fold
increase in cell numbers) that perinatal BPA exposure as it
nowoccurs inmost of the populationwill increase relative
risk 1.6-fold. Because breast cancer affects 1 in 8 women,
ie, 12.5% of women, this means that 20%, ie, 1 in 5
women could be affected in the future (Figure 4).
A potential mechanism underlying the increased sensi-
tivity to progesterone is an increase in the number of PR
cells that is reflected in increased inductionofRANKLand
wnt4 in response to ex vivo progesterone stimulation (83).
Hence, perinatal exposure to endocrine disruptors that
mimic estrogens like BPA may increase breast cancer risk
by increasing the sensitivity of themammary epithelium to
progesterone and amplifying the biological response dur-
ing each menstrual cycle (Figure 4).
Clearly, the mechanisms of endocrine disruption are
more complex, because BPA acts at multiple levels on
mammary gland development (85).Wehave a longway to
go to say in which way findings in C57Bl6 mice are rele-
vant to humanhealth; yet, at this point,we cannot exclude
that current exposures may result in more breast cancer
cases. Efforts should be made to broaden the definition of
carcinogen to account for the biological complexities of
hormone regulation that are so important for homeostasis
and hence our wellbeing, in particular the epigenetic
changes that hormones elicit, which can result in perma-
nent remodeling of the chromatin with transgenerational
effects (86, 87).
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